Rinath Jeselsohn

Oncology

450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 105 publications

Tailoring Management for Invasive Lobular Carcinoma: Imaging, Surgical Treatment, and Systemic Therapy Considerations.

Tailoring Management for Invasive Lobular Carcinoma: Imaging, Surgical Treatment, and Systemic Therapy Considerations.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: April 07, 2026

SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 20, 2026

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 20, 2026

Visceral adiposity and breast cancer outcomes: transcriptomic analysis of the tumor microenvironment by intrinsic subtype.

Visceral adiposity and breast cancer outcomes: transcriptomic analysis of the tumor microenvironment by intrinsic subtype.

Journal: Breast cancer research : BCR

Published: March 02, 2026

PROFET predicts continuous gene expression dynamics from scRNA-seq data to elucidate heterogeneity of cancer treatment responses.

PROFET predicts continuous gene expression dynamics from scRNA-seq data to elucidate heterogeneity of cancer treatment responses.

Journal: Cell systems

Published: December 17, 2025

Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial.

Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial.

Journal: Annals of surgical oncology

Published: September 12, 2025

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

Journal: NPJ precision oncology

Published: September 06, 2025

Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer.

Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer.

Journal: ESMO open

Published: August 21, 2025

The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination.

The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination.

Journal: JCI insight

Published: August 20, 2025

ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance.

ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance.

Journal: Genome medicine

Published: August 18, 2025

Super-resolution microscopy reveals distinct epigenetic states regulated by estrogen receptor activity.

Super-resolution microscopy reveals distinct epigenetic states regulated by estrogen receptor activity.

Journal: bioRxiv : the preprint server for biology

Published: July 16, 2025

Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer.

Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer.

Journal: NPJ breast cancer

Published: July 14, 2025

Showing 1-12 of 105

Last Updated: 09/26/2026